Fumaric Acid

Fumaric Acid

SCHEMBL956029

CN(CCCN1C(=O)CS[C@H]1c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)CCOc1ccc2c(c1)OOC2.O=C(O)/C=C/C(=O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453983 0.95
SCHEMBL7902213 0.95
SCHEMBL8102946 0.93
SCHEMBL8112243 0.93
SCHEMBL8116961 0.92
SCHEMBL8118032 0.92
SCHEMBL8103052 0.91
Fumaric Acid SCHEMBL956032 0.89 ALDH1A1 (0.47)
SCHEMBL8111914 0.88 GAA (0.43)
SCHEMBL8114156 0.87 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906919-B2 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers OZTEO PTY LTD (AU) 2014-12-09 US claimed
US-20120172363-A1 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers Ozleo Pty Ltd (AU) 2012-07-05 US claimed
US-6191281-B1 CRYSTALS OF A SALT OF (S)-(-)-2-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-3-(3-(N-METHYL-N -(2-(3,4-METHYLENEDIOXYPHENOXY)ETHYL)AMINO)PROPYL)-1, 3-THIAZOLIDINE-4-ONE, USEFUL AS ANTIISCHEMIC AGENT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-02-20 US claimed
EP-0974591-A1 CRYSTALLINE FUMARATE OF 2-PHENYL-1,3-THIAZOLIDINE-4-ON DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-01-26 EP claimed
US-8906919-B2 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers OZTEO PTY LTD (AU) 2014-12-09 US disclosed
US-20120172363-A1 Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers Ozleo Pty Ltd (AU) 2012-07-05 US disclosed
EP-2453893-A1 TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS Ozteo Pty Ltd (AU) 2012-05-23 EP disclosed
WO-2011003129-A1 TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS OZTEO PTY LTD (AU) 2011-01-13 WO disclosed
US-6191281-B1 CRYSTALS OF A SALT OF (S)-(-)-2-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-3-(3-(N-METHYL-N -(2-(3,4-METHYLENEDIOXYPHENOXY)ETHYL)AMINO)PROPYL)-1, 3-THIAZOLIDINE-4-ONE, USEFUL AS ANTIISCHEMIC AGENT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-02-20 US disclosed
EP-0974591-A1 CRYSTALLINE FUMARATE OF 2-PHENYL-1,3-THIAZOLIDINE-4-ON DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-01-26 EP disclosed